Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients
| Authors | |
|---|---|
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Hematological Oncology |
| MU Faculty or unit | |
| Citation | |
| Web | https://onlinelibrary.wiley.com/doi/10.1002/hon.2908 |
| Doi | http://dx.doi.org/10.1002/hon.2908 |
| Keywords | COVID-19; remdesivir; hematological patients |
| Description | Immunocompromised patients with hematological malignancies are at high risk for a severe course of COVID-19 (Coronavirus Disease 2019) with a deadly outcome.1, 2 With remdesivir use, several randomized trials have recorded abbreviated recovery periods, lower mortality, and positive consequences of early treatment initiation.3, 4 Based on randomized trial results, the FDA has approved remdesivir for the treatment of COVID-19. Regarding convalescent plasma (CP), evidence from recently published large trials implies that early administration of high-titer CP is most efficacious.5 However, no published studies assessing the effect of remdesivir or CP in COVID-19 have included a substantial proportion of hematooncology patients, and available data are limited to case reports.6, 7 In view of this dearth of data, we decided to analyze the efficacy of early combination therapy of remdesivir and high-titer CP among hematological patients. This treatment strategy was implemented after observing several grim COVID-19 outcomes among these patients. |